$CGEN News

All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy

Compugen: Better Runway Ahead Of MAIA

Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancing COM701 with Strong Cash ...

Compugen Q2 Earnings Call Highlights

Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript

Compugen Q2 EPS $(0.07), Inline, Sales $2.602M Beat $1.606M Estimate

Compugen to Participate in BTIG Biotechnology Conference 2026

Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026

Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress

Compugen Presents Trial-In-Progress Poster On MAIA-Ovarian Adaptive Platform Trial Of COM701, Potential Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026

Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions

Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript

Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026

Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026

Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development

Why The Narrative Around Compugen (NasdaqCM:CGEN) Is Shifting After Analyst Resets And New Views

Compugen Q1 2026 Earnings Call: Complete Transcript

Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Leerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5

Compugen Ltd. Q1 2026 Earnings Call Summary